Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293242 | 1.00 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2290326 | 1.00 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL1459125 | 0.98 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22662486 | 0.91 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2846888 | 0.90 | CA1 (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9911449 | 0.88 | CA1 (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1134561 | 0.86 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14342160 | 0.86 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1428345 | 0.86 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10012149 | 0.86 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119176813-A | Tricyclic heterocyclic compound with FGFR inhibition effect, pharmaceutical composition containing tricyclic heterocyclic compound and application of pharmaceutical composition | 上海科恩泰生物医药科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| WO-2021078021-A1 | SMALL MOLECULAR COMPOUND | 嘉兴特科罗生物科技有限公司 | 2021-04-29 | — | — | WO | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020142557-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| CN-1195340-A | Inhibitors of farnesyl-protein transferase | MERCK & CO INC (US) | 1998-10-07 | — | — | CN | disclosed |
| US-4859779-A | ENZYME INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4837353-A | 2-/N-PHENYLALKYL-N-FORMYL/AMINO-3-HYDROXY-2-PROPENOIC ACID DERIVATIVES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0284375-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4762850-A | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | CTSK 2282/4885CTSS 2006/4885CA1 1348/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | CTSK 1045/4885CTSS 2616/4885CA1 485/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | CTSK 1202/4885CTSS 1406/4885CA1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.